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Zhengbo Song1,2†, Xiangyu Jin1,2† and Yiping Zhang1,2*Abstract
Background: Because of the rarity of thymoma, no randomized trials have prospectively detected the prognosis
and optimal treatment for type B2 thymoma. The aim of this study is to investigate the treatment and prognosis
for patients with type B2 thymoma.
Methods: We retrospectively evaluated the outcome of 42 patients with type B2 thymoma who were treated
between 1995 and 2010 in Zhejiang Cancer Hospital. Survival curves were plotted using the Kaplan–Meier method.
The Cox proportional hazard model was used for multivariate analysis.
Results: The current study included 42 patients. The 5-year disease-free survival and overall survival rates were
62.8% and 84.9%, respectively. There were significant differences in disease-free survival and overall survival among
different Masaoka stages (both P < 0.001). Univariate and multivariate analysis revealed that Masaoka stage was
associated with disease-free survival and overall survival (P = 0.00 and 0.001, respectively).
Conclusions: Our results indicate that Masaoka stage affects disease-free survival and overall survival of patients with
type B2 thymoma.
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Thymoma has a prevalence of 0.1 to 0.4/100,000 and ac-
counts for less than 1% of all malignant tumors [1]. The
B2 type of thymoma is defined as a tumor in which the
neoplastic epithelial component appears as scattered plump
cells with vesicular nuclei and distinct nucleoli among a
heavy population of lymphocytes by the World Health
Organization (WHO) classification [2].
The proportion of B2 types reported is about 20% for
all thymomas [3,4]. The B2 type of thymoma has been
shown to have a better prognosis than thymic carcinoma
and worse than types A, AB and B1 [5,6]. Because of the
rarity of thymoma, no randomized trials have prospect-
ively detected the prognosis and optimal treatment of
type B2 thymoma. No consensus guidelines for the treat-
ment of type B2 thymoma have currently been defined.
In the present study, we retrospectively evaluated the treat-
ment and prognosis of patients with type B2 thymoma,* Correspondence: yipingzhang@yahoo.cn
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unless otherwise stated.and the long-term efficacy of multimodality therapy in this
setting.Methods
Patients
A total of 252 patients underwent a surgical resection
for thymoma between January 1995 and January 2010 in
Zhejiang Cancer Hospital. In this period, 42 patients
were diagnosed as type B2. The stage of thymoma was
classified based on the Masaoka staging system. All pa-
tients had been pathologically confirmed as having type
B2 thymoma (WHO histologic classification) by surgery
or needle biopsy. Recurrence or metastases were con-
firmed using chest computed tomography, as well as
ultrasound and/or computed tomography of the abdo-
men. The study was approved by the ethics committee
of Zhejiang Cancer Hospital.Follow-up
For patients who underwent a surgical intervention, all
were examined in the outpatient clinic at 3-month inter-
vals for the first 2 years and, thereafter, at 6-month inter-
vals. For patients at an advanced stage, the follow-ups
were at 6 to 8 weeks apart. The last censoring date fortd. This is an Open Access article distributed under the terms of the Creative
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tients was 70 months, ranging from 25 to 180 months.
Statistical analysis
The statistical analysis was performed using SPSS version
17 (SPSS Inc, Chicago, IL, USA), assuming that P < 0.05 is
statistically significant. The survival curves were generated
using the Kaplan–Meier method. Disease-free survival
(DFS) encompassed the time from surgery to documented
progression or death from any cause. The definition of
overall survival (OS) was determined from the date of sur-
gery and the last known follow-up or date of death.
Results
Patient characteristics
The patients’ characteristics are detailed in Table 1. The
median age was 54 years (range 15 to 71 years). Of the
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No 36 85.7biopsy. At the time of diagnosis, 31 were asymptom-
atic, while 11 presented with clinical symptoms or
signs, including 8 with myasthenia gravis and 3 with
chest pain. Stage I was diagnosed for 14 patients, stage
II for 11 patients, stage III for 10 patients and stage IV
for 7 patients.Treatment and recurrence or metastasis
Of the 35 patients who underwent surgery, 30 had an R0
resection and 5 had an R1 or R2 resection. Also 22 patients
were treated with radiation therapy (doses ranged from
40 to 60 Gy). Six patients received chemotherapy as a
regimen with CAP (cyclophosphamide + doxorubicin +
cisplatin, n = 2), carboplatin and paclitaxel (n = 2) or
VIP (ifosfamide + cisplatin + etoposide, n = 2).
Recurrence developed in 17 patients. Ten of seventeen
patients had local recurrence, and pleural relapse was
the most common site (six of ten patients). Seven pa-
tients had distant metastases after surgery. The sites of
the distant metastases were the lung (three cases), liver
(two cases) and bone (two cases).Table 2 Univariate analysis of disease-free and overall
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Table 3 Multivariate survival analysis for disease-free and overall survival of the 42 patients
Disease-free survival Overall survival
Variable Hazard ratio 95% confidence interval P Hazard ratio 95% confidence interval P
Gender (male vs female ) 0.448 0.144–1.395 0.166 0.275 0.069–1.100 0.068
Age (≥50 vs <50) 1.058 0.249–4.507 0.939 0.777 0.134–4.491 0.778
Resection (yes vs no) 0.782 0.113–5.429 0.804 1.937 0.219–17.092 0.552
Adjuvant treatment (yes vs no) 1.385 0.421–4.555 0.591 2.853 0.649–12.545 0.165
Tumor size (>7 cm vs ≤7 cm) 3.079 0.657–14.417 0.153 2.514 0.371–17.041 0.345
Myasthenia gravis (yes vs no) 1.204 0.182–7.945 0.847 0.598 0.046–7.813 0.695
Stage (III + IV vs I + II ) 6.163 2.421–15.691 0.000 5.462 1.923–15.514 0.001
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The 5-year DFS rates were 62.8% (85.7%, 70.1%, 47.3%
and 0.00% in stages I, II, III and IV, respectively). The
5-year OS rates were 84.9% (91.7%, 88.9%, 72.0% and
34.3% in stages I, II, III and IV, respectively).
The effects of age, gender, adjuvant treatment, myas-
thenia gravis, resection and Masaoka stage on DFS and
OS were studied in both uni- and multivariate analyses
(Tables 2 and 3). In the univariate analysis, resection and
Masaoka stage were predictive of DFS and OS (Figures 1
and 2). Masaoka stage was shown to have a significant
influence on DFS and OS in the multivariate analysis.Discussion
To the best of our knowledge, this is the first report that
has focused on the prognosis and treatment of type B2
thymoma. Our results suggest that Masaoka stage could
affect the survival of patients with type B2 thymoma.Figure 1 Comparison of disease-free survival for different Masaoka stType B2 thymoma has a moderate aggressive nature
compared with other subtypes. About half of patients
were staged as III or IV at the first diagnosis [7,8]. In
contrast, most patients with type B3 and thymic carcin-
oma were at an advanced stage [9,10]. In the current
study, 40.5% patients were at stages III or IV of type B2
at diagnosis. The 5-year survival rate was around 50%
for type B3 thymoma, while it was 90% for types B1, AB
and A. The 5-year survival rate for type B2 thymoma
was about 60% to 70% in previous reports [4,5]. The 5-year
survival rate was 62.8% in our study, which is similar to
previous reports.
The effect of different treatments is discussed contro-
versially in previous studies. It is generally accepted that
surgery is the mainstay treatment, and R0 resection is
one of the most independent prognostic factors for
thymoma. However, some reports have shown that there
was no survival difference for patients who undergo
complete resection compared with patient undergoingages (P < 0.001).
Figure 2 Comparison of overall survival for different Masaoka stages (P < 0.001).
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were DFS and OS differences between complete and
incomplete resection patients. However, the differences
for DFS and OS were not significant by multivariate
analysis, possibly because of the small number of pa-
tients in our study. Adjuvant radiotherapy is not usu-
ally recommended for stage I thymoma in the National
Comprehensive Cancer Network guideline and recom-
mended category is low in stage II and III thymoma. In
our study, adjuvant radiotherapy and chemotherapy
had no effect on DFS and OS in multivariate analyses.
Considering selection bias and the small sample size,
no conclusions can be made for the efficacy of adju-
vant treatment.
The Masaoka staging system has been shown to be an
independent prognostic factor for all subtypes of thymoma
in previous research [12,13]. Our present study demon-
strated that Masaoka stage was an independent prognostic
factor for type B2 thymoma in both uni- and multivariate
analyses (P = 0.00 and 0.001, respectively). There were
significant survival differences among different stages
in terms of DFS and OS (Figures 1 and 2).
Our study is limited by its retrospective design and its
small number of patients. In addition, there were only
17 patients with recurrence or metastasis. Therefore, the
outcome must be explained carefully. However, with few
cases in previous clinical studies, our retrospective study
may also be considered to be meaningful.
Conclusions
In conclusion, Masaoka stage remains the mainstay for
type B2 thymoma. Given the nature of retrospectiveanalysis, our results should be confirmed by further pro-
spective studies.
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